Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer.

ABSTRACT:

Background/aim

Triple-negative breast cancers represent 15% of all mammary malignancies and encompass several entities with different genomic characteristics. Among these, luminal androgen receptor (LAR) tumors express the androgen receptor (AR) and are characterized by a genomic profile which resembles luminal breast cancers. Moreover, LAR malignancies are usually enriched in PIK3CA, KMTC, CDH, NF1, and AKT1 alterations. Still, molecular features, clinical behavior and prognosis of this variant remain controversial, while identification of effective treatments represents an unmet medical need. Additionally, the predictive role of the AR is unclear.

Materials and methods

We performed an extensive next generation sequencing analysis using a commercially available panel in a c

SUBMITTER: Stella S 

PROVIDER: S-EPMC9247873 | biostudies-literature | 2022 Jul-Aug

REPOSITORIES: biostudies-literature